In REIMAGINE 2, CagriSema lowered HbA1c by an additional 0.16 percentage points versus semaglutide 2.4 mg at week 68. The difference was statistically significant. CagriSema remains investigational in the United States [1] [4].
The REDEFINE 1 weight-management trial enrolled participants without type 2 diabetes. REIMAGINE 2 asked a separate question in adults with type 2 diabetes and a BMI of at least 25 whose blood sugar was inadequately controlled on metformin, with or without an SGLT2 inhibitor [1].
REIMAGINE 2 compared CagriSema with semaglutide
Mean baseline HbA1c across the trial was 8.2%. At week 68, estimated reductions were 1.91 percentage points on CagriSema (2.4 mg of each ingredient) and 1.75 points on semaglutide 2.4 mg. The estimated difference was −0.16 points (95% CI −0.27 to −0.05, p=0.0035). These estimates model what would happen if participants stayed on assigned treatment without rescue medication [1].
At least one adverse event was reported by 524 of 603 participants (86.9%) on the higher-dose combination and 491 of 605 (81.2%) on semaglutide 2.4 mg. Gastrointestinal disorders were the most frequently reported category in the active treatment groups [1].
REIMAGINE 3 tested an add-on to basal insulin
REIMAGINE 3 randomized 274 adults whose blood sugar was inadequately controlled on basal insulin, with or without metformin. At week 40, HbA1c fell by an estimated 2.33 and 2.10 percentage points in the two CagriSema groups versus 0.66 points with pooled placebo[2].
All groups continued basal insulin. The trial had no semaglutide-only arm, so it cannot isolate cagrilintide’s contribution. Our guide to low blood sugar with insulin and GLP-1 medicines explains why the background treatment matters. REIMAGINE 3 reported no severe hypoglycemia during the trial, which does not establish the risk for an individual patient [2].
IcoSema is a different combination
IcoSema combines weekly insulin icodec with semaglutide and received EU marketing authorization as Kyinsu in November 2025. Its trials used different comparators from the CagriSema program [5].
Pooling two COMBINE trials with 1,970 adults gave an HbA1c difference of −0.37 percentage points (95% CI −0.95 to 0.21). The I² of 98% indicates very high inconsistency. The trials compared IcoSema with different insulin regimens, which may help explain the difference. Pooled between-group differences favored IcoSema for weight (−6.10 kg) and systolic blood pressure (−2.45 mmHg). Those measures cannot establish whether it prevents heart attacks or strokes [3].
U.S. approval status
As of November 14, 2026, CagriSema remained investigational in the U.S. Novo Nordisk’s December 2025 FDA application was for weight management. The application does not establish approval for weight management or type 2 diabetes [4]. FDA also says cagrilintide cannot be used in compounding under federal law [6].